Form 4: Entrada Therapeutics CEO Dipal Doshi Sells 1,000 Shares Under 10b5-1 Trading Plan
SEC Form 4
Entrada Therapeutics CEO Dipal Doshi sold 1,000 shares of common stock on June 13, 2024, at a weighted average price of $16.1736, according to a Form 4 filing.
Summary
- On June 13, 2024, Dipal Doshi, CEO of Entrada Therapeutics, sold 1,000 shares of common stock.
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2023.
- The shares were sold at prices ranging from $15.87 to $16.46, with a weighted average price of $16.1736.
- Following the transaction, Doshi directly owns 336,375 shares of Entrada Therapeutics.
- The transaction was reported on a Form 4 filing with the Securities and Exchange Commission.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by the CEO. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Sales by company executives are a normal part of corporate governance. The fact that the sale was executed under a 10b5-1 trading plan suggests that the sale was pre-planned and not based on any inside information.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the sale was conducted under a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| May 15, 2023 | Date of adoption of Rule 10b5-1 trading plan |
| June 13, 2024 | Date of stock sale transaction |
| June 14, 2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.